A Single Dose Versus Two Doses of Tranexamic Acid for Extracapsular Hip Fractures.

Autor:	Jiganti M; Orthopedics, Good Samaritan Regional Medical Center, Corvallis, USA., Pipitone O; Graduate Medical Education - Biostatistics, Good Samaritan Regional Medical Center, Corvallis, USA., Than J; Orthopedics, Good Samaritan Regional Medical Center, Corvallis, USA., Stanley R; Orthopedics, The Corvallis Clinic, Corvallis, USA., Passanise A; Orthopedics, The Corvallis Clinic, Corvallis, USA., Krumrey J; Orthopedics and Traumatology, Good Samaritan Regional Medical Center, Corvallis, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Jan 14; Vol. 14 (1), pp. e21239. Date of Electronic Publication: 2022 Jan 14 (Print Publication: 2022).
DOI:	10.7759/cureus.21239
Abstrakt:	Objective In this study, we aimed to compare the effectiveness of one dose of tranexamic acid (TXA) at the time of hospital admission versus two doses of TXA (one at the time of hospital admission and another dose intraoperatively) in reducing perioperative total blood loss in patients with extracapsular hip fractures. Methods This retrospective cohort study included 80 patients from a single institution who underwent surgical fixation for extracapsular hip fractures. Forty patients received a single dose of 1 gram of TXA at the time of hospital admission (per standardized protocol of an ongoing research study at the time), and 40 patients received the same dose of TXA on hospital admission as well as a second dose of 1 gram of TXA intraoperatively at the time of incision (per standard practice change following the completion of the research study). The primary study outcome of interest was total blood loss, which was calculated by estimating blood volume via Nadler's formula followed by calculating the total blood loss with the hemoglobin dilution method. Secondary outcomes included blood transfusion rates, hospital length of stay (LOS), and 30-day mortality. Results Patient gender, age, the American Society of Anesthesiologists (ASA) score, procedure length, fracture type, hardware type, and hemoglobin on hospital arrival were similar across the study groups (all p>0.05), though the twice-dosed group had a higher average BMI (26.4 kg/m 2 vs. 24 kg/m 2 , p=0.04). When adjusting for BMI, the twice-dosed group was estimated to have a slightly larger but non-significant difference in total blood loss (115-ml difference, 95% CI: 158.2-389.3, p=0.40) compared to the single-dose TXA group. More patients in the twice-dosed group required blood transfusion compared to the single-dose TXA group, though this was not statistically significant (30.0% vs. 17.5%, adjusted OR=1.64, 95% CI: 0.55-5.12, p=0.38). The distribution of hospital LOS and 30-day mortality rates were similar across the groups (p=0.13 and p>0.99). Conclusion In the setting of surgically treated extracapsular hip fractures, patients who received one dose of TXA at the time of hospital admission and a second intraoperative dose of TXA did not demonstrate significant differences in total blood loss or a need for blood transfusion compared to patients who only received a single dose of TXA at the time of hospital admission. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Jiganti et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu